Tilray Brands, Inc.
HealthcareNASDAQ:TLRY · NASDAQ Global Select
-$0.14 today
Vol 3.14M · Avg 4.67M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.2B of revenue converted into -$1.8B of net income for the selected period. Gross margin is 27.6% and net margin is -150.1%, showing how much revenue survives after costs and taxes. EPS is $-18.70, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B +4.8% | $1.1B +27.3% | $844.7M +6.6% | $792.1M +27.8% | $619.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $796.9M +3.4% | $770.7M +19.2% | $646.8M +0.3% | $644.9M +36.9% | $470.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $330.1M +8.5% | $304.3M +53.7% | $198.0M +34.4% | $147.3M -1.0% | $148.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 29.3% +1.0pp | 28.3% +4.9pp | 23.4% +4.8pp | 18.6% -5.4pp | 24.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $389.7K -55.0% | $865.2K -5.8% | $918.6K -52.0% | $1.9M +90.9% | $1.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $356.1M +4.2% | $341.6M +9.8% | $311.1M +33.3% | $233.4M +24.1% | $188.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.5B +538.3% | $542.4M -73.4% | $2.0B +122.8% | $916.7M +197.3% | $308.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $183.2M +5.9% | $172.9M -1.4% | $175.3M -10.0% | $194.9M +137.9% | $81.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$2.9B -2841.4% | -$99.3M +94.2% | -$1.7B -452.2% | -$310.6M -4.4% | -$297.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -259.0% -249.8pp | -9.2% +193.8pp | -203.1% -163.8pp | -39.2% +8.8pp | -48.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$3.1B -1215.5% | -$238.1M +87.1% | -$1.8B -139.8% | -$769.5M -382.0% | -$159.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -277.9% -255.8pp | -22.1% +196.3pp | -218.4% -121.3pp | -97.1% -71.4pp | -25.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $15.6M -10.7% | $17.5M -60.7% | $44.5M +200.7% | $14.8M +318.6% | $3.5M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $56.7M -15.5% | $67.1M +6.9% | $62.8M +25.5% | $50.0M +34.0% | $37.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$27.0M +73.3% | -$101.2M +6.7% | -$108.4M -150.7% | $214.0M +183.2% | -$257.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$3.2B -831.1% | -$339.3M +82.6% | -$2.0B -251.6% | -$555.5M -33.3% | -$416.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -280.3% -248.8pp | -31.6% +199.7pp | -231.2% -161.1pp | -70.1% -2.9pp | -67.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$166.1M -357.9% | -$36.3M -274.9% | -$9.7M -17.3% | -$8.2M +23.9% | -$10.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$3.0B -798.9% | -$333.8M +82.9% | -$2.0B -225.5% | -$601.0M -35.4% | -$443.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -266.3% -235.2pp | -31.1% +200.6pp | -231.6% -155.8pp | -75.9% -4.3pp | -71.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$34 -651.1% | -$5 +85.8% | -$32 -218.9% | -$10 +27.0% | -$14 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$34 -651.1% | -$5 +85.8% | -$32 -218.9% | -$10 +27.0% | -$14 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $89.0M +19.9% | $74.3M +20.2% | $61.8M +28.4% | $48.1M +78.5% | $27.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $89.0M +19.9% | $74.3M +20.2% | $61.8M +28.4% | $48.1M +78.5% | $27.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Neogen Corporation
NASDAQ:NEOG
$1.98B
Dynavax Technologies Corporation
DVAX
$1.82B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Alvotech
NASDAQ:ALVO
$1.30B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Evotec SE
NASDAQ:EVO
$966.11M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TLRY generate?
Tilray Brands, Inc. (TLRY) reported $1.13B of revenue in fiscal 2025.
Is TLRY profitable?
Tilray Brands, Inc. (TLRY) reported -$3,000,620,016.00 of net income, with a net margin of -266.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.